FDA
-
-
-
-
-
-
-
Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Intensity Therapeutics (INTS) Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial
-
-
-
-
-
-
-
Intensity Therapeutics (INTS) Granted Orphan Drug Designation for the three key ingredients in INT230-6
-
-
-
-
322,222 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

